{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T23:08:28Z","timestamp":1788736108064,"version":"build-2803163510"},"reference-count":180,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023368","name":"Eisai Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008207","name":"AstraZeneca Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008207","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ctrv.2026.103194","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T15:04:08Z","timestamp":1784214248000},"page":"103194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Expanding the path to cure - a narrative review on optimizing multimodality sequencing in HCC"],"prefix":"10.1016","volume":"149","author":[{"given":"Howard J.","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma M.","family":"Dunne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur","family":"Brahmania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent C.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Knox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason K.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prosanto","family":"Chaudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Ramjeesingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter T.W.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilidio","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro C.","family":"Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Sapisochin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2026.103194_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2026.103194_bb0010","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103194_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(23)00186-9","article-title":"Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept","volume":"24","author":"Vitale","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0020","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/hep.31187","article-title":"Treatment of hepatocellular carcinoma in the precision medicine era: from treatment stage migration to therapeutic hierarchy","volume":"72","author":"Vitale","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2026.103194_bb0025","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.jhep.2024.01.010","article-title":"Merits and boundaries of the BCLC staging and treatment algorithm: learning from the past to improve the future with a novel proposal","volume":"80","author":"Trevisani","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0030","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jhep.2025.10.020","article-title":"BCLC strategy for prognosis prediction and treatment recommendations: the 2026 update","volume":"84","author":"Reig","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0035","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1007\/s00432-021-03528-3","article-title":"Treatment stage migration and treatment sequences in patients with hepatocellular carcinoma: drawbacks and opportunities","volume":"147","author":"Wehling","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0040","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S2468-1253(24)00434-5","article-title":"Precision surgery for hepatocellular carcinoma","volume":"10","author":"Magyar","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0045","author":"National Cancer Institute"},{"key":"10.1016\/j.ctrv.2026.103194_bb0050","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/s41416-023-02188-z","article-title":"\u2018Potentially curative therapies\u2019 for hepatocellular carcinoma: how many patients can actually be cured?","volume":"128","author":"Cucchetti","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2026.103194_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines14040877","article-title":"Hepatocellular carcinoma bridging and downstaging: advances in locoregional therapy","volume":"14","author":"Fite","year":"2026","journal-title":"Biomedicines"},{"key":"10.1016\/j.ctrv.2026.103194_bb0060","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/HEP.0000000000000726","article-title":"Adjuvant and neoadjuvant therapies for hepatocellular carcinoma","volume":"82","author":"Vogel","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2026.103194_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17030507","article-title":"Evolving indications for liver transplantation for hepatocellular carcinoma following the Milan criteria","volume":"17","author":"Kokudo","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2026.103194_bb0070","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.soc.2023.07.004","article-title":"Expanding indications for surgical resection in hepatocellular carcinoma: what is the evidence?","volume":"33","author":"Chang","year":"2024","journal-title":"Surg Oncol Clin N Am"},{"key":"10.1016\/j.ctrv.2026.103194_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17193251","article-title":"Recent advances in ablative therapies for hepatocellular carcinoma","volume":"17","author":"Abu Zahra","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2026.103194_bb0080","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL clinical practice guidelines on the management of hepatocellular carcinoma","volume":"82","author":"Sangro","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0085","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.prro.2023.08.016","article-title":"Defining minimum treatment parameters of ablative radiation therapy in patients with hepatocellular carcinoma: an expert consensus","volume":"14","author":"Yanagihara","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0090","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jhep.2025.01.005","article-title":"Radiation segmentectomy for early hepatocellular carcinoma is curative","volume":"82","author":"Salem","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0095","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S2468-1253(22)00091-7","article-title":"Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-Centre, single-arm study","volume":"7","author":"Kim","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0100","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jvir.2024.02.017","article-title":"Combination and optimal sequencing of systemic and locoregional therapies in hepatocellular carcinoma: proceedings from the Society of Interventional Radiology Foundation: research consensus panel","volume":"35","author":"Thornton","year":"2024","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0105","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2468-1253(24)00247-4","article-title":"Combination locoregional and systemic therapies in hepatocellular carcinoma","volume":"10","author":"Zhong","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0110","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1159\/000519749","article-title":"A novel treatment strategy for patients with intermediate-stage HCC who are not suitable for TACE: upfront systemic therapy followed by curative conversion","volume":"10","author":"Kudo","year":"2021","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ctrv.2026.103194_bb0115","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","article-title":"Hepatocellular carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"36","author":"Vogel","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0120","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/HEP.0000000000001269","article-title":"Critical update: AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"82","author":"Taddei","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2026.103194_bb0125","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2026.103194_bb0130","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/SLA.0000000000002889","article-title":"Liver transplantation and hepatic resection can achieve cure for hepatocellular carcinoma","volume":"268","author":"Pinna","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.ctrv.2026.103194_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.surg.2024.10.008","article-title":"Comparative analysis of treatment modalities for solitary, small (\u22643 cm) hepatocellular carcinoma: a systematic review and network meta-analysis of oncologic outcomes","volume":"180","author":"Choi","year":"2025","journal-title":"Surgery"},{"key":"10.1016\/j.ctrv.2026.103194_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1366607","article-title":"Liver transplantation vs liver resection in HCC: promoting extensive collaborative research through a survival meta-analysis of meta-analyses","volume":"14","author":"Martinino","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0145","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s12672-025-03226-3","article-title":"Managing hepatocellular carcinoma recurrence after liver transplantation: emerging role of immune checkpoint inhibitors","volume":"16","author":"Rezaee-Zavareh","year":"2025","journal-title":"Discov Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0150","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.3390\/jcm14197009","article-title":"Hepatocellular carcinoma recurrence after liver transplantation: current insights and future directions","volume":"14","author":"Parraga","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.ctrv.2026.103194_bb0155","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1097\/HEP.0000000000001297","article-title":"A prospective multicenter validation of RETREAT for posttransplantation HCC recurrence prediction","volume":"82","author":"Li","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2026.103194_bb0160","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/jhbp.1248","article-title":"Bridging therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis on intention-to-treat outcomes","volume":"30","author":"Di Martino","year":"2023","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.ctrv.2026.103194_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16112081","article-title":"Hepatocellular carcinoma: the evolving role of systemic therapies as a bridging treatment to liver transplantation","volume":"16","author":"Saleh","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2026.103194_bb0170","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jvir.2024.10.034","article-title":"Yttrium-90 radioembolization has become the Most utilized bridging treatment for liver transplant candidates in the United States","volume":"36","author":"Salem","year":"2025","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0175","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/LVT.0000000000000743","article-title":"Evolving trends and comparative outcomes of bridging transarterial locoregional therapy in liver transplant candidates with hepatocellular carcinoma","volume":"32","author":"Fakhoury","year":"2026","journal-title":"Liver Transpl"},{"key":"10.1016\/j.ctrv.2026.103194_bb0180","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2016.08.029","article-title":"Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma","volume":"151","author":"Salem","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ctrv.2026.103194_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2021.07.048","article-title":"National Trends and waitlist outcomes of locoregional therapy among liver transplant candidates with hepatocellular carcinoma in the United States","volume":"20","author":"Kwong","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0190","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jhep.2017.02.022","article-title":"Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis","volume":"67","author":"Sapisochin","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0195","article-title":"SBRT for bridging and downstaging HCC before transplant","volume":"7","author":"Li","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.ctrv.2026.103194_bb0200","article-title":"Outcomes after stereotactic body radiation therapy as a bridging modality to liver transplantation for hepatocellular carcinoma","volume":"6","author":"Garg","year":"2021","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0205","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.15998","article-title":"Stereotactic body radiotherapy and liver transplant for liver cancer: a nonrandomized controlled trial","volume":"7","author":"Lee","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ctrv.2026.103194_bb0210","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ijrobp.2025.12.023","article-title":"Safety and feasibility of stereotactic body radiation therapy for patients with hepatocellular carcinoma and advanced cirrhosis awaiting liver transplantation: a prospective pilot clinical trial","volume":"124","author":"Rahmani","year":"2026","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"key":"10.1016\/j.ctrv.2026.103194_bb0215","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1200\/JCO.2020.38.15_suppl.4586","article-title":"A randomized phase II feasibility study of individualized stereotactic body radiation therapy (SBRT) versus transarterial chemoembolization (TACE) with DEBDOX beads as a bridge to transplant in hepatocellular carcinoma (HCC)","volume":"38","author":"Nugent","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0220","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16132374","article-title":"Liver transplantation for hepatocellular carcinoma in the era of immune checkpoint inhibitors","volume":"16","author":"De Stefano","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2026.103194_bb0225","doi-asserted-by":"crossref","first-page":"1689820","DOI":"10.3389\/fonc.2025.1689820","article-title":"Navigating the risks: a systematic review of immune checkpoint inhibitor therapy before liver transplant for hepatocellular carcinoma and its impact on allograft rejection and survival outcomes","volume":"15","author":"Liu","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0230","article-title":"Liver resection and transplantation in the era of checkpoint inhibitors","volume":"6","author":"Tabrizian","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.ctrv.2026.103194_bb0235","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13185371","article-title":"Innovations in liver preservation techniques for transplants from donors after circulatory death: a special focus on transplant oncology","volume":"13","author":"Finotti","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.ctrv.2026.103194_bb0240","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jhep.2025.01.042","article-title":"Deceased donor liver utilisation and assessment: consensus guidelines from the European liver and intestine transplant association","volume":"82","author":"Hessheimer","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0245","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MOT.0000000000001230","article-title":"Normothermic regional perfusion and liver transplant: expanding the donation after circulatory death donor pool","volume":"30","author":"Stahl","year":"2025","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.ctrv.2026.103194_bb0250","doi-asserted-by":"crossref","first-page":"11259","DOI":"10.1038\/s41467-025-66133-9","article-title":"The promise of organ rejuvenation to overcome the shortage in organ transplantation","volume":"16","author":"Kayumov","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2026.103194_bb0255","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa0804525","article-title":"Gene expression in fixed tissues and outcome in hepatocellular carcinoma","volume":"359","author":"Hoshida","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103194_bb0260","doi-asserted-by":"crossref","first-page":"48688","DOI":"10.18632\/oncotarget.16231","article-title":"Adverse genomic alterations and stemness features are induced by field cancerization in the microenvironment of hepatocellular carcinomas","volume":"8","author":"Castven","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2026.103194_bb0265","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103194_bb0270","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1245\/s10434-020-08452-3","article-title":"Recurrence patterns and outcomes after resection of hepatocellular carcinoma within and beyond the Barcelona clinic liver Cancer criteria","volume":"27","author":"Tsilimigras","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0275","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.21037\/atm-20-6116","article-title":"Predicting the survival rate of patients with hepatocellular carcinoma after thermal ablation by nomograms","volume":"8","author":"Zhou","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ctrv.2026.103194_bb0280","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1245\/s10434-022-11790-z","article-title":"Clinical features of recurrence after hepatic resection for early-stage hepatocellular carcinoma and long-term survival outcomes of patients with recurrence: a multi-institutional analysis","volume":"29","author":"Yao","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0285","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1200\/JCO.2026.44.2_suppl.477","article-title":"Adjuvant pembrolizumab for participants with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation: The phase 3 keynote-937 study","author":"Chan","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0290","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jhep.2026.01.006","article-title":"Updated data from IMbrave050: adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma","volume":"84","author":"Yopp","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0295","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251357719","article-title":"Role of immune checkpoint inhibitor combinations in resectable and unresectable, embolization-eligible hepatocellular carcinoma","volume":"17","author":"Meyers","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0300","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41591-023-02786-7","article-title":"Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103194_bb0305","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1158\/1078-0432.CCR-17-2899","article-title":"Adjuvant Transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103194_bb0310","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40880-018-0331-y","article-title":"Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety","volume":"38","author":"Wei","year":"2018","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.ctrv.2026.103194_bb0315","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1001\/jamasurg.2024.0506","article-title":"Adjuvant Transarterial chemoembolization with sorafenib for portal vein tumor Thrombus: a randomized clinical trial","volume":"159","author":"Peng","year":"2024","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ctrv.2026.103194_bb0320","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1097\/HEP.0000000000001233","article-title":"Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection: a randomized, open-label, phase 3 trial","volume":"82","author":"Ma","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2026.103194_bb0325","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.radonc.2019.05.006","article-title":"Postoperative adjuvant IMRT for patients with HCC and portal vein tumor thrombus: an open-label randomized controlled trial","volume":"140","author":"Sun","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0330","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00423-024-03249-4","article-title":"Radiotherapy is superior to transarterial chemoembolization as adjuvant therapy after narrow-margin hepatectomy in patients with hepatocellular carcinoma: a single-center prospective randomized study","volume":"409","author":"Bai","year":"2024","journal-title":"Langenbeck\u2019s Arch Surg"},{"key":"10.1016\/j.ctrv.2026.103194_bb0335","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ejca.2022.02.012","article-title":"Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with microvascular invasion: a randomised controlled trial","volume":"166","author":"Shi","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2026.103194_bb0340","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S2468-1253(19)30422-4","article-title":"Adjuvant (131)I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial","volume":"5","author":"Li","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0345","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.ejso.2019.06.031","article-title":"Adjuvant transarterial chemoembolization improves survival outcomes in hepatocellular carcinoma with microvascular invasion: a systematic review and meta-analysis","volume":"45","author":"Chen","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0350","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.clinre.2019.06.012","article-title":"Adjuvant transarterial chemoembolization after curative hepatectomy for hepatocellular carcinoma with microvascular invasion: a systematic review and meta-analysis","volume":"44","author":"Shen","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0355","doi-asserted-by":"crossref","first-page":"554","DOI":"10.4240\/wjgs.v16.i2.554","article-title":"Comparative effectiveness of several adjuvant therapies after hepatectomy for hepatocellular carcinoma patients with microvascular invasion","volume":"16","author":"Pei","year":"2024","journal-title":"World J Gastrointest Surg"},{"key":"10.1016\/j.ctrv.2026.103194_bb0360","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.radonc.2022.08.019","article-title":"Systematic review of adjuvant external beam radiotherapy for hepatocellular carcinoma following radical hepatectomy","volume":"175","author":"Wang","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0365","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000541622","article-title":"Chinese expert consensus on the whole-course management of hepatocellular carcinoma (2023 edition)","volume":"14","author":"Yang","year":"2025","journal-title":"Liver Cancer (Basel)"},{"key":"10.1016\/j.ctrv.2026.103194_bb0370","doi-asserted-by":"crossref","first-page":"19","DOI":"10.17998\/jlc.2025.02.03","article-title":"A concise review of updated global guidelines for the management of hepatocellular carcinoma: 2017-2024","volume":"25","author":"Shin","year":"2025","journal-title":"J Liver Cancer"},{"key":"10.1016\/j.ctrv.2026.103194_bb0375","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009722","article-title":"Immune checkpoint blockade: timing is everything","volume":"12","author":"Sinicrope","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2026.103194_bb0380","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1158\/1078-0432.CCR-19-2209","article-title":"Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen\u2013Specific T Cells","volume":"26","author":"Friedman","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103194_bb0385","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","article-title":"Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa","volume":"15","author":"Khan","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0390","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103194_bb0395","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030600","article-title":"Neoadjuvant immune checkpoint inhibitors for resectable hepatocellular carcinoma: a systematic review and meta-analysis","volume":"15","author":"Zhao","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2026.103194_bb0400","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1200\/JCO.2024.42.16_suppl.4120","article-title":"Perioperative pembrolizumab and lenvatinib for resectable hepatocellular carcinoma: A single-arm, multi-center, phase II trial (NeoLEAP-HCC)","volume":"42","author":"Sun","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0405","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1200\/JCO.2023.41.16_suppl.4129","article-title":"Neoadjuvant immunotherapy with ipilimumab plus nivolumab and radiologically and pathologically quantifiable responses through modulation of the tumour microenvironment in resectable hepatocellular carcinoma","volume":"41","author":"D\u2019Alessio","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0410","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2468-1253(21)00427-1","article-title":"Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial","volume":"7","author":"Kaseb","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0415","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S2468-1253(21)00385-X","article-title":"Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial","volume":"7","author":"Marron","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0420","doi-asserted-by":"crossref","first-page":"e16304","DOI":"10.1200\/JCO.2025.43.16_suppl.e16304","article-title":"Neoadjuvant immune-checkpoint blockade therapy in combination with TACE for resectable hepatocellular carcinoma with high recurrence risk: A phase II, single-arm clinical trial (MORNING)","volume":"43","author":"Kuang","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0425","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(24)00457-1","article-title":"Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis","volume":"25","author":"D\u2019Alessio","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0430","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/S0140-6736(25)01720-9","article-title":"Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2\/3 trial","volume":"406","author":"Wang","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103194_bb0435","article-title":"Pathological response \u226590% predicts survival in HCC treated with neoadjuvant loco-regional therapies: a retrospective cohort study","volume":"8","author":"Ou-Yang","year":"2026","journal-title":"JHEP Rep"},{"key":"10.1016\/j.ctrv.2026.103194_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2025.101587","article-title":"Prognostic value of radiological and pathological complete response following immune-based conversion therapy in patients with unresectable hepatocellular carcinoma (GUIDANCE004)","volume":"7","author":"Yang","year":"2025","journal-title":"JHEP Reports"},{"key":"10.1016\/j.ctrv.2026.103194_bb0445","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1159\/000536376","article-title":"Prognostic value of pathological response for patients with unresectable hepatocellular carcinoma undergoing conversion surgery","volume":"13","author":"Zeng","year":"2024","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ctrv.2026.103194_bb0450","doi-asserted-by":"crossref","first-page":"4140","DOI":"10.1200\/JCO.2025.43.16_suppl.4140","article-title":"Prognostic significance of pathological response in unresectable hepatocellular carcinoma treated with immune checkpoint inhibitor-based conversion therapy","volume":"43","author":"Zheng","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0455","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41590-024-01992-w","article-title":"Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma","volume":"25","author":"Shu","year":"2024","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0460","doi-asserted-by":"crossref","first-page":"472","DOI":"10.21037\/hbsn-22-527","article-title":"Pathologic assessment of hepatocellular carcinoma in the era of immunotherapy: a narrative review","volume":"13","author":"Wang","year":"2024","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10.1016\/j.ctrv.2026.103194_bb0465","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0470","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1554499","article-title":"Synergies between radiotherapy and immunotherapy: a systematic review from mechanism to clinical application","volume":"16","author":"Jiang","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0475","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1200\/JCO.18.02184","article-title":"Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study","volume":"37","author":"Wei","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0480","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1097\/JS9.0000000000000574","article-title":"Neoadjuvant intensity modulated radiotherapy for a single and small (\u22645 cm) hepatitis B virus-related hepatocellular carcinoma predicted to have high risks of microvascular invasion: a randomized clinical trial","volume":"109","author":"Wei","year":"2023","journal-title":"Int J Surg"},{"key":"10.1016\/j.ctrv.2026.103194_bb0485","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/HEP.0000000000001433","article-title":"Tertiary lymphoid structures in HCC: influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy","volume":"83","author":"Su","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2026.103194_bb0490","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.annonc.2024.05.190","article-title":"181P circulating tumor DNA (ctDNA) testing for recurrence and treatment response monitoring in hepatocellular carcinoma (HCC)","volume":"35","author":"Abdelrahim","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0495","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202503144R","article-title":"Single-cell multi-omics reveals B2M-mediated myeloid reprogramming and constructs a predictive model for early hepatocellular carcinoma recurrence","volume":"39","author":"Tan","year":"2025","journal-title":"FASEB J"},{"key":"10.1016\/j.ctrv.2026.103194_bb0500","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1200\/JCO.2025.43.16_suppl.3137","article-title":"Multi-omics cohort-based prediction model for early relapse of hepatocellular carcinoma post-surgery","volume":"43","author":"Song","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0505","article-title":"A deep learning radiopathomic signature predicts recurrence risk of hepatocellular carcinoma after hepatectomy","volume":"9","author":"Wang","year":"2026","journal-title":"Commun Biol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0510","doi-asserted-by":"crossref","first-page":"oyaf368","DOI":"10.1093\/oncolo\/oyaf368","article-title":"An early relapse prediction model based on pathological features following neoadjuvant immunotherapy for hepatocellular carcinoma","volume":"31","author":"Pang","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2026.103194_bb0515","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1111\/liv.12750","article-title":"Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma","volume":"35","author":"Kolligs","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.ctrv.2026.103194_bb0520","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s00270-014-1012-0","article-title":"Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma","volume":"38","author":"Pitton","year":"2015","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0525","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1148\/radiol.211806","article-title":"(90)Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase II randomized controlled trial","volume":"303","author":"Dhondt","year":"2022","journal-title":"Radiology"},{"key":"10.1016\/j.ctrv.2026.103194_bb0530","doi-asserted-by":"crossref","first-page":"6739","DOI":"10.1016\/j.acra.2025.06.008","article-title":"Transarterial radioembolization with Yttrium-90 and SIRT versus conventional transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"32","author":"de Alc\u00e2ntara","year":"2025","journal-title":"Acad Radiol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0535","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ijrobp.2023.03.064","article-title":"Transarterial chemoembolization with drug-eluting beads versus stereotactic body radiation therapy for hepatocellular carcinoma: outcomes from a multicenter, randomized, phase 2 trial (the TRENDY trial)","volume":"117","author":"M\u00e9ndez Romero","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2026.103194_bb0540","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1002\/cncr.34965","article-title":"Proton beam radiotherapy versus transarterial chemoembolization for hepatocellular carcinoma: results of a randomized clinical trial","volume":"129","author":"Bush","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2026.103194_bb0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.09.063","article-title":"LBA51 IKF-035\/ABC-HCC: a phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma","volume":"36","author":"Galle","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0550","doi-asserted-by":"crossref","first-page":"8802","DOI":"10.3390\/curroncol29110692","article-title":"Stereotactic Radiotherapy after Incomplete Transarterial (Chemo-) Embolization (TAE\\TACE) versus Exclusive TAE or TACE for Treatment of Inoperable HCC: A Phase III Trial (NCT02323360)","volume":"29","author":"Comito","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0555","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ijrobp.2024.09.021","article-title":"External beam radiation therapy after Transarterial chemoembolization versus Transarterial chemoembolization alone for treatment of inoperable hepatocellular carcinoma: a randomized phase 3 trial","volume":"121","author":"Chen","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2026.103194_bb0560","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/02656736.2021.1887941","article-title":"Combined therapy with conventional trans-arterial chemoembolization (cTACE) and microwave ablation (MWA) for hepatocellular carcinoma >3-<5cm","volume":"38","author":"Zaitoun","year":"2021","journal-title":"Int J Hyperth"},{"key":"10.1016\/j.ctrv.2026.103194_bb0565","doi-asserted-by":"crossref","first-page":"414","DOI":"10.29271\/jcpsp.2019.05.414","article-title":"Comparison of efficiency of TACE plus HIFU and TACE alone on patients with primary liver Cancer","volume":"29","author":"Luo","year":"2019","journal-title":"J Coll Physicians Surg Pak"},{"key":"10.1016\/j.ctrv.2026.103194_bb0570","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/hep.27290","article-title":"Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial","volume":"60","author":"Kudo","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2026.103194_bb0575","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000522547","article-title":"Final results of TACTICS: a randomized, prospective trial comparing Transarterial chemoembolization plus sorafenib to Transarterial chemoembolization alone in patients with unresectable hepatocellular carcinoma","volume":"11","author":"Kudo","year":"2022","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ctrv.2026.103194_bb0580","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2019-318934","article-title":"Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial","volume":"69","author":"Kudo","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.ctrv.2026.103194_bb0585","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S2468-1253(17)30290-X","article-title":"Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study","volume":"3","author":"Kudo","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0590","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamaoncol.2024.1831","article-title":"Survival in patients with recurrent intermediate-stage hepatocellular carcinoma: sorafenib plus TACE vs TACE alone randomized clinical trial","volume":"10","author":"Fan","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0595","volume":"9","author":"Duan","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ctrv.2026.103194_bb0600","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103194_bb0605","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103194_bb0610","volume":"36","author":"Dong","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0615","volume":"44","author":"Abou-Alfa","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0620","series-title":"LBA2 - Tumour response analyses by RECIST v1.1 and mRECIST in the phase III EMERALD-3 study of tremelimumab plus durvalumab with or without lenvatinib plus transarterial chemoembolisation (TACE) in embolisation-eligible hepatocellular carcinoma (eeHCC)","author":"Erinjeri","year":"2026"},{"key":"10.1016\/j.ctrv.2026.103194_bb0625","author":"Merck"},{"key":"10.1016\/j.ctrv.2026.103194_bb0630","series-title":"183O - Overall survival (OS) in EMERALD-1: A phase III study of durvalumab (D) \u00b1 bevacizumab (B) and transarterial chemoembolisation (TACE) in participants (pts) with unresectable embolisation-eligible hepatocellular carcinoma (eeHCC)","author":"Sangro","year":"2026"},{"key":"10.1016\/j.ctrv.2026.103194_bb0635","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1200\/JCO-25-01796","article-title":"Transarterial chemoembolization combined with Camrelizumab and Rivoceranib for unresectable hepatocellular carcinoma (CHANCE2005\/CARES-005): a randomized phase II trial","volume":"44","author":"Zhu","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0640","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000538558","article-title":"Immune checkpoint inhibitors plus anti-VEGF\/tyrosine kinase inhibitors combined with TACE (triple therapy) in unresectable hepatocellular carcinoma","volume":"13","author":"Kudo","year":"2024","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ctrv.2026.103194_bb0645","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1159\/000539301","article-title":"A changing role of Transarterial chemoembolization in the era of immune checkpoint inhibitor plus anti-VEGF\/TKI plus Transarterial chemoembolization: from Total embolization to partial embolization (immune boost Transarterial chemoembolization)","volume":"13","author":"Kudo","year":"2024","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ctrv.2026.103194_bb0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2020.05.012","article-title":"Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: results of the PRODIGE 16 study","volume":"45","author":"Turpin","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0655","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00270-019-02405-4","article-title":"Selective versus non-selective Transarterial chemoembolization via the intercostal artery for the treatment of hepatocellular carcinoma","volume":"43","author":"Hyun","year":"2020","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0660","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/HEP.0000000000001229","volume":"82","author":"Yang","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2026.103194_bb0665","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41392-022-01235-0","article-title":"Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)","volume":"8","author":"Zhu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ctrv.2026.103194_bb0670","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.ctrv.2026.103194_bb0675","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103194_bb0680","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jhep.2025.03.033","article-title":"Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC","volume":"83","author":"Rimassa","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0685","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0690","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103194_bb0695","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103194_bb0700","doi-asserted-by":"crossref","first-page":"20220179","DOI":"10.1259\/bjr.20220179","article-title":"Summary of key guidelines for locoregional treatment of HCC in Asia, Europe, south and North America","volume":"95","author":"Garcia-Monaco","year":"2022","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0705","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2018.11.029","article-title":"Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: the phase III STAH trial","volume":"70","author":"Park","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0710","first-page":"1","article-title":"Transarterial chemoembolization plus sorafenib versus sorafenib alone in advanced hepatocellular carcinoma (SELECT): a multicenter, phase 3, randomized, controlled trial","author":"Zhao","year":"2025","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ctrv.2026.103194_bb0715","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO.22.00392","article-title":"Lenvatinib combined with Transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH)","volume":"41","author":"Peng","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0720","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","article-title":"Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma","volume":"71","author":"Ricke","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0725","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamaoncol.2024.5403","article-title":"Stereotactic body radiotherapy vs sorafenib alone in hepatocellular carcinoma: the NRG oncology\/RTOG 1112 phase 3 randomized clinical trial","volume":"11","author":"Dawson","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0730","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14205102","article-title":"Downstaging therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis on intention-to-treat outcomes","volume":"14","author":"Di Martino","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2026.103194_bb0735","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1055\/s-0040-1716565","article-title":"The key role of staging definitions for assessment of downstaging for hepatocellular carcinoma","volume":"41","author":"Yao","year":"2021","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.ctrv.2026.103194_bb0740","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.cgh.2022.02.018","article-title":"UNOS Down-staging criteria for liver transplantation of hepatocellular carcinoma: systematic review and Meta-analysis of 25 studies","volume":"21","author":"Tan","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0745","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1053\/j.gastro.2021.07.033","article-title":"Downstaging outcomes for hepatocellular carcinoma: results from the Multicenter evaluation of reduction in tumor size before liver transplantation (MERITS-LT) consortium","volume":"161","author":"Mehta","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ctrv.2026.103194_bb0750","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S1470-2045(20)30224-2","article-title":"Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b\/3 trial","volume":"21","author":"Mazzaferro","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0755","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1002\/cam4.4090","article-title":"Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: results from the IMbrave150 trial","volume":"10","author":"Salem","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.ctrv.2026.103194_bb0760","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.2_suppl.LBA479","article-title":"Nivolumab plus ipilimumab vs lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): 4-year follow-up of CheckMate 9DW","volume":"44","author":"Galle","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0765","doi-asserted-by":"crossref","first-page":"S1229","DOI":"10.1016\/j.annonc.2024.08.2277","article-title":"LBA3 Transarterial chemoembolization (TACE) with or without lenvatinib (len) + pembrolizumab (pembro) for intermediate-stage hepatocellular carcinoma (HCC): phase III LEAP-012 study","volume":"35","author":"Llovet","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0770","first-page":"891","article-title":"Neoadjuvant Cabozantinib and nivolumab converts locally advanced HCC into Resectable disease with enhanced antitumor immunity","volume":"2","author":"Ho","year":"2021","journal-title":"Nat Can"},{"key":"10.1016\/j.ctrv.2026.103194_bb0775","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.2092","article-title":"946P Sintilimab plus lenvatinib as conversion therapy in patients with unresectable hepatocellular carcinoma: a prospective, non-randomized, open-label, phase II, expansion cohort study","volume":"34","author":"Lu","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0780","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S2468-1253(22)00339-9","article-title":"Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial","volume":"8","author":"Chiang","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0785","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2026.44.2_suppl.540","volume":"44","author":"Chiang","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0790","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2023.41.16_suppl.4124","volume":"41","author":"Chiang","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0795","doi-asserted-by":"crossref","first-page":"6647","DOI":"10.1097\/JS9.0000000000001813","article-title":"Pembrolizumab in combination with LEnvatinib in participants with hepatocellular carcinoma before liver transplant as neoadjuvant TherapY-PLENTY pilot study","volume":"110","author":"Lv","year":"2024","journal-title":"Int J Surg"},{"key":"10.1016\/j.ctrv.2026.103194_bb0800","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.08.2099","article-title":"1469MO liver resection versus continued atezolizumab plus bevacizumab (atezo\/bev) in locally advanced hepatocellular carcinoma (HCC) after atezo\/bev treatment (TALENTop): a multicenter, open-label, randomized phase III trial","volume":"36","author":"Sun","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0805","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000547723","article-title":"Assessment of survival benefits derived from surgical resection subsequent to the attainment of complete response upon triple therapy in hepatocellular carcinoma: a Multicenter study","volume":"15","author":"Zhang","year":"2026","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ctrv.2026.103194_bb0810","first-page":"687","article-title":"Survival benefit of hepatectomy after complete or partial response to conversion therapy in unresectable hepatocellular carcinoma (GUIDANCE003): a Multicenter study","volume":"14","author":"Yang","year":"2025","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ctrv.2026.103194_bb0815","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2024.11.005","article-title":"The use of immunotherapy pre-liver transplant","volume":"82","author":"Aceituno","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0820","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jhep.2024.06.042","article-title":"Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: a systematic review and individual patient data meta-analysis","volume":"82","author":"Rezaee-Zavareh","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0825","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15184574","article-title":"Immunotherapy and liver transplantation: a narrative review of basic and clinical data","volume":"15","author":"Wassmer","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2026.103194_bb0830","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/oncolo\/oyad327","article-title":"Transarterial radioembolization for management of hepatocellular carcinoma","volume":"29","author":"Badar","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2026.103194_bb0835","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial","volume":"6","author":"Garin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0840","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.ctrv.2026.103194_bb0845","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1111\/j.1600-6143.2009.02695.x","article-title":"A comparative analysis of Transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization","volume":"9","author":"Lewandowski","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ctrv.2026.103194_bb0850","doi-asserted-by":"crossref","DOI":"10.1007\/s00270-026-04379-6","article-title":"Efficacy of Transarterial radioembolization and Transarterial chemoembolization as downstaging or bridging strategies for hepatocellular carcinoma before liver transplantation: a systematic review and Meta-analysis","author":"Xie","year":"2026","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0855","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2026.44.2_suppl.504","article-title":"PROACTIF: final results from the largest prospective real-world study of 1196 primary liver cancer patients (PLC) treated with yttrium-90 (Y90) glass transarterial radioembolization (TARE)","volume":"44","author":"Guiu","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0860","doi-asserted-by":"crossref","DOI":"10.5306\/wjco.v16.i4.100729","article-title":"Multidisciplinary tumor board is associated with improved survival in patients with hepatocellular carcinoma after liver transplantation","volume":"16","author":"Zhang","year":"2025","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0865","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210730","article-title":"Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients","volume":"14","author":"Sinn","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2026.103194_bb0870","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3390\/curroncol28010042","article-title":"The impact of geography in hepatocellular carcinoma: a retrospective population based study","volume":"28","author":"Yu","year":"2021","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0875","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.3390\/cancers13194849","article-title":"Development and implementation of multidisciplinary liver tumor boards in the veterans affairs health care system: a 10-year experience","volume":"13","author":"Rabiee","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2026.103194_bb0880","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000143","article-title":"Multidisciplinary care for patients with HCC: a systematic review and meta-analysis","volume":"7","author":"Seif El Dahan","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.ctrv.2026.103194_bb0885","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1245\/s10434-013-3413-8","article-title":"Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome","volume":"21","author":"Yopp","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103194_bb0890","doi-asserted-by":"crossref","first-page":"171","DOI":"10.17998\/jlc.2024.08.30","article-title":"Multidisciplinary approaches to downstaging hepatocellular carcinoma: present and future","volume":"24","author":"Hwang","year":"2024","journal-title":"Journal of Liver Cancer"},{"key":"10.1016\/j.ctrv.2026.103194_bb0895","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7403","article-title":"Multidisciplinary management of immunotherapy-related adverse events in solid tumors: an inter-institutional and telemedicine-based working team","volume":"13","author":"Iaculli","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.ctrv.2026.103194_bb0900","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.3390\/cancers12113446","article-title":"Multidisciplinary clinical approach to Cancer patients with immune-related adverse events induced by checkpoint inhibitors","volume":"12","author":"Londo\u00f1o","year":"2020","journal-title":"Cancers (Basel)"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226001088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226001088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T22:29:40Z","timestamp":1788733780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226001088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":180,"alternative-id":["S0305737226001088"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103194","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expanding the path to cure - a narrative review on optimizing multimodality sequencing in HCC","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103194","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103194"}}